Existing pipeline agents are not expected to address the unmet needs of the rheumatoid arthritis space by 2025, says a report by GlobalData.
Titled ‘PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2025’, the report states that agents currently in pipeline will compete for the same patient populations as currently available options when launched.
Individualised medicine is one area where research is ongoing, but likely to remain in the initial stages by the end of the forecast period in 2025. Biomarker discovery is another area where ongoing research will help in understanding rheumatoid arthritis in patients at a molecular level.
Unmet needs such as personalised treatments and earlier diagnosis are more likely to be met through research efforts and better understanding of the rheumatoid arthritis pathophysiology, explains Kavita Rainova, MSc, Senior Healthcare Analyst at GlobalData.
Since biologics are expensive, patients and physicians need to establish a regimen involving tapering of medications or ceasing of treatment if response rate is good and the patient is longer suffering from the disease, opines Rainova.
Drugs with novel mechanisms of action will be popular in the market, but will face challenges in the wake of shifting treatment paradigms, the report cautions.
Drug developers should take drug tapering into account, while developing the pricing strategy for their drugs. Qualified patients should also be provided with rebates as a financial incentive to those who cannot afford the medications, adds the report.